|
|
Volumn 350, Issue , 2015, Pages
|
|
Thousands of patients in England to get new hepatitis C drugs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DACLATASVIR;
LEDIPASVIR;
OMBITASVIR;
PARITAPREVIR;
PEGINTERFERON;
RIBAVIRIN;
RITONAVIR;
SIMEPREVIR;
SOFOSBUVIR;
ABT-267;
ABT-450;
ANILIDE;
ANTIVIRUS AGENT;
BENZIMIDAZOLE DERIVATIVE;
BMS-790052;
CARBAMIC ACID DERIVATIVE;
FLUORENE DERIVATIVE;
FUSED HETEROCYCLIC RINGS;
IMIDAZOLE DERIVATIVE;
MACROCYCLIC COMPOUND;
SULFONAMIDE;
URIDINE PHOSPHATE;
CLINICAL EFFECTIVENESS;
COST EFFECTIVENESS ANALYSIS;
DISEASE ASSOCIATION;
DRUG COST;
END STAGE LIVER DISEASE;
HEALTH CARE ACCESS;
HEPATITIS C;
HUMAN;
INCIDENCE;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
MORTALITY;
NATIONAL HEALTH SERVICE;
NOTE;
PRIORITY JOURNAL;
TREATMENT DURATION;
TREATMENT RESPONSE;
UNITED KINGDOM;
ANALOGS AND DERIVATIVES;
ECONOMICS;
HEPATITIS C, CHRONIC;
PUBLIC HEALTH;
ANILIDES;
ANTIVIRAL AGENTS;
BENZIMIDAZOLES;
CARBAMATES;
ENGLAND;
FLUORENES;
HEPATITIS C, CHRONIC;
HETEROCYCLIC COMPOUNDS, 3-RING;
HUMANS;
IMIDAZOLES;
MACROCYCLIC COMPOUNDS;
PUBLIC HEALTH;
SULFONAMIDES;
URIDINE MONOPHOSPHATE;
|
|
EID: 84936792213
PISSN: 09598146
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.h3222 Document Type: Note |
|
Times cited : (1)
|
|
References (3)
|
